COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08JHZ
|
|||
Drug Name |
BLD-2660
|
|||
Synonyms |
BLD 2660
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2 | [1] | |
Therapeutic Class |
Antiviral Agents
|
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN calpain-1/calpain small subunit 1 heterodimer (CAPN1/CAPNS1) | Target Info | Inhibitor | [1], [2] |
Dimeric calpains and ACE2 are co-expressed in respiratory epithelial cells, the site of both viral entry and predominant early lung injury in COVID-19. Inhibition of calpains 1 and 2 has resulted in anti-SARS-CoV activity by reducing infectious virus particle replication and hence production. BLD-2660, an inhibitor of dimeric calpains (calpain 1 or 2 and calpain small subunit 1 dimer), can effectively inhibit SARS-CoV-2 replication. | ||||
HUMAN calpain-2/calpain small subunit 1 heterodimer (CAPN2/CAPNS1) | Target Info | Inhibitor | [1], [2] | |
Dimeric calpains and ACE2 are co-expressed in respiratory epithelial cells, the site of both viral entry and predominant early lung injury in COVID-19. Inhibition of calpains 1 and 2 has resulted in anti-SARS-CoV activity by reducing infectious virus particle replication and hence production. BLD-2660, an inhibitor of dimeric calpains (calpain 1 or 2 and calpain small subunit 1 dimer), can effectively inhibit SARS-CoV-2 replication. |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04334460) Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects. U.S. National Institutes of Health. | |||
2 | Blade is a leader in repairing tissue fibrosis and organ dysfunction |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.